Search

Your search keyword '"Petr Jansky"' showing total 50 results

Search Constraints

Start Over You searched for: Author "Petr Jansky" Remove constraint Author: "Petr Jansky" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
50 results on '"Petr Jansky"'

Search Results

1. Impact of patient selection in clinical trials: application of ROCKET AF and ARISTOTLE criteria in GARFIELD-AF

2. Rhythm versus rate control in patients with newly diagnosed atrial fibrillation – Observations from the GARFIELD-AF registry

3. On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease

4. Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF

5. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

6. Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial

7. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

8. 36-month clinical outcomes of patients with venous thromboembolism

9. Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized trial

10. An evaluation of the effects of the European Commission’s proposals for the Common Consolidated Corporate Tax Base

11. Is Panama really your tax haven? Secrecy jurisdictions and the countries they harm

12. Multinational corporations and tax havens: evidence from country-by-country reporting

13. Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin

14. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation

15. Lowering cholesterol, blood pressure, or both to prevent cardiovascular events : results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants

16. Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation

17. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

18. Design and baseline characteristics of participants in the <scp>R</scp> esearching cardiovascular <scp>E</scp> vents with a <scp>W</scp> eekly <scp>IN</scp> cretin in <scp>D</scp> iabetes ( <scp>REWIND</scp> ) trial on the cardiovascular effects of dulaglutide

19. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis

20. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients

21. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease

22. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease

23. 360Role of cardioversion in the management of non-valvular atrial fibrillation: insights from the GARFIELD-AF registry

24. Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention : An Analysis of the HOPE-3 Trial

25. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE) : an international, randomised, placebo-controlled trial

26. Rivaroxaban with or without aspirin in patients with stable coronary artery disease : an international, randomised, double-blind, placebo-controlled trial

27. Warfarin loading dose guided by pharmacogenetics is effective and safe in cardioembolic stroke patients - a randomized, prospective study

28. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide

29. Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin

30. Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries

31. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial

32. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study

33. Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy

34. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease

35. Tratamiento prehospitalario de los pacientes con IAMCEST. Una declaración científica del Working Group Acute Cardiac Care de la European Society of Cardiology

36. Pre-hospital treatment of STEMI patients. A scientific statement of the Working Group Acute Cardiac Care of the European Society of Cardiology

37. The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial

38. BODY MASS INDEX AND OUTCOMES WITH APIXABAN VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION IN THE ARISTOTLE (APIXABAN FOR REDUCTION IN STROKE AND OTHER THROMBOEMBOLIC EVENTS IN ATRIAL FIBRILLATION) TRIAL

39. AORTIC STENOSIS, BUT NOT MITRAL OR AORTIC REGURGITATION, IS ASSOCIATED WITH ADVERSE OUTCOMES WITH ATRIAL FIBRILLATION: RESULTS FROM THE ARISTOTLE TRIAL

41. Structural connectivity-based predictors of cognitive impairment in stroke patients attributable to aging.

42. Abstract 20326: Impact of Gender on Clinical Outcomes in Non-Valvular Atrial Fibrillation: Contemporary Perspective From the GARFIELD Registry

43. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes

44. Consumer Demand System Estimation and Value Added Tax Reforms in the Czech Republic

45. International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2

46. Outcomes after rhythm versus rate control in patients with atrial fibrillation: the international prospective GARFIELD registry

47. Outcomes at 1 year in atrial fibrillation patients with versus without an acute coronary syndrome: insights from the prospective GARFIELD Registry

48. Pre-hospital treatment of STEMI patients. A scientific statement of the Working Group Acute Cardiac Care of the European Society of Cardiology

49. Impact of the changes in excise duties on households in the Czech Republic

50. An evaluation of the effects of the European Commission's proposals for the Common Consolidated Corporate Tax Base

Catalog

Books, media, physical & digital resources